(Q39170853)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28277829%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

title

Etelcalcetide for the treatment of secondary hyperparathyroidism (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28277829%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28277829%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Masafumi Fukagawa

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28277829%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1

Naoto Hamano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28277829%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

language of work or name

English

0 references

publication date

15 March 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28277829%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

5 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28277829%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28277829%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28277829%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

page(s)

529-534

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28277829%20AND%20SRC:MED&resulttype=core&format=json

Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.

5 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Calcimimetics with potent and selective activity on the parathyroid calcium receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Calcium-sensing receptor in the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Critical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel d-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2017.1303482

10.1080/14656566.2017.1303482

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28277829%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference